Details

<p>List of Contributors VII</p> <p>Foreword XIII</p> <p>Preface XV</p> <p><b>Part One Strategies & Resistance 1</b></p> <p>1 Comparison of Anti‐ectoparasite and Anti‐endoparasite Therapies and Control Strategies 3<i><br />Debra J. Woods*, Tom L. McTier, and Andrew A. DeRosa</i></p> <p>2 vaccination Against Ticks 25<br /><i>Theo P.M. Schetters*</i></p> <p>3 Blocking Transmission of vector‐borne Diseases  43<br /><i>Sandra Schorderet‐Weber, Sandra Noack, Paul M. Selzer, and Ronald Kaminsky*</i></p> <p>4 The Threat and Reality of Drug Resistance in the Cattle Tick Rhipicephalus (Boophilus) microplus  95<br /><i>Heinz Sager*, Léonore Lovis, Christian Epe, and Ronald Kaminsky</i></p> <p>5 Monitoring Drug Sensitivity in Cattle Ticks 109<br /><i>Leonore Lovis, Christian Epe, Ronald Kaminsky, and Heinz Sager*</i></p> <p>6 New Developments in the Control of Human Lice 119<br /><i>John M. Clark*</i></p> <p><b>Part Two Screens & Models 139</b></p> <p>7 Molecular Targets to Impair Blood Meal Processing in Ticks 141<br /><i>Petr Kopáček*, Jan Perner, Daniel Sojka, Radek Šíma, and Ondřej Hajdušek</i></p> <p>8 Whole‐organism Screens for Ectoparasites 167<br /><i>Jeffrey N. Clark* and Cedric J. Pearce</i></p> <p>9 In vitro Feeding Methods for Hematophagous Arthropods and Their Application in Drug Discovery 187<br /><i>Ard M. Nijhof* and Katharine R. Tyson</i></p> <p>10 Testing in Laboratory Animal Models for Ectoparasiticide Discovery and Development 205<br /><i>Sandra Schorderet‐Weber* and Ronald Kaminsky</i></p> <p>11 Testing in Target Hosts for Ectoparasiticide Discovery and Development 223<br /><i>Jeffrey N. Clark*</i></p> <p><b>Part Three Isoxazolines 243</b></p> <p>12 Isoxazolines: A Novel Chemotype Highly Effective on Ectoparasites 245<br /><i>Tina Weber and Paul M. Selzer*</i></p> <p>13 The Discovery of Afoxolaner: A New Ectoparasiticide for Dogs  259<br /><i>Ming Xu, Jeffrey K. Long, George P. Lahm*, Wesley L. Shoop, Daniel Cordova, Ty Wagerle, Ben K. Smith, Thomas F. Pahutski, Rafael Shapiro, Michael Mahaffey, Eric J. Hartline, Brandon R. Gould, Molly E. Waddell, Richard G. McDowell, John B. Kinney, Gail S. Jones, Robert F. Dietrich, Mark E. Schroeder, Daniel F. Rhoades, Eric A. Benner, and Pat N. Confalone</i></p> <p>14 Development of Afoxolaner as a New Ectoparasiticide for Dogs 273<br /><i>Laura Letendre*, Diane Larsen, and Mark Soll</i></p> <p>15 Discovery, Development, and Commercialization of Sarolaner (Simparica^®), A Novel Oral Isoxazoline Ectoparasiticide for Dogs 295<br /><i>Debra J. Woods* and Tom L. McTier</i></p> <p>16 Isoxazolines: Preeminent Ectoparasiticides of the Early Twenty‐first Century 319<br /><i>Alan Long*</i></p> <p>Index 353</p>

Dr. Charles Q. Meng earned his PhD degree in Organic Chemistry from the University of Zurich in 1991. Upon completing postdoctoral research at Roche (Basel) and the University of Montreal he worked for Allelix Biopharmaceuticals (Mississauga, Ontario) on migraine drug discovery and AtheroGenics (Alpharetta, Georgia) on cardiovascular drug discovery. In 2007 Dr. Meng joined the pharmaceutical discovery and research group of Merial, a Sanofi company then and part of Boehringer Ingelheim now, focusing on antiparasitic drug discovery for animal health. He is an inventor of 25 issued US patents and an author of over 30 publications of original research, reviews, commentaries and book chapters. <br> <br> Dr. Ann E. Sluder earned a PhD in Biochemistry from Duke University in 1988 studying transcription biochemistry in Drosophila melanogaster. During postdoctoral studies at Harvard Medical School and Massachusetts General Hospital she initiated a research program focused on nuclear receptor transcription factors in the nematode Caenorhabditis elegans, which she expanded to include parasitic nematodes while an Assistant Professor of Cellular Biology at the University of Georgia. From 2000-2014 Dr. Sluder worked in drug discovery for antiparasitics, orphan neuromuscular diseases and viral and fungal infections at two biotechnology companies. In 2015 she joined the Vaccine and Immunotherapy Center of the Massachusetts General Hospital, managing preclinical development programs in infectious diseases, cancer, and diabetes. <br> <br> Prof. Dr. Paul M. Selzer studied Biology, Parasitology, and Biochemistry at the University of Tubingen, Germany, where he also received his PhD in Biochemistry. He spent three years at the Molecular Design Institute and the Tropical Disease Research Laboratory at the University of California, San Francisco. During his career he has worked as a researcher and scientific manager for several pharmaceutical companies, and is currently holding a management position in antiparasitic drug discovery at Boehringer Ingelheim Animal Health. He is also a visiting professor at the Interfaculty Institute of Biochemistry of the University of Tubingen, DE and an honorary professor of the Department of Infection, Immunity, and Inflammation at the University of Glasgow, UK.<br>

DE